A Phase 1 interventional study of TAK-438 and TAK-438 Placebo in Erosive Esophagitis(EE) and Gastroesophageal Reflux Disease (GERD), sponsored by Takeda. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-19.
Sponsored by Takeda · Phase 1, Interventional, and Basic science
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel, multiple-dose schedule.
The drug being tested in this study is called TAK-438. TAK-438 is being tested to find a safe and well-tolerated dose. This study looked at pharmacokinetic (effect of the body on the drug) and pharmacodynamic properties (effect of the drug on the body) as well as look at lab results and side effects in people who took TAK-438. This study was designed as a randomized, sequential-panel, multiple repeat dose study.
The study population consisted of 4 Cohorts with 12 participants in each Cohort; with 9 participants randomized to receive a single dose of TAK-438, and 3 participants to receive placebo. Participants in each Cohort received a single dose of study drug once daily after a 10-hour fast. The starting dose was 10 mg followed by administrations of 20, 40, and 30 mg.
This single-centre trial was conducted in the United Kingdom. The overall time to participate in this study was up to 37 days. Participants made 2 visits to the clinic for screening, one 11-day period of confinement to the clinic, and 2 further visits after the confinement period. All participants were contacted by telephone 7 days after last dose of study drug for a follow-up assessment.
1,067 studies on the registry are indexed under Gastroesophageal Reflux; 188 are open to participants now.
This study's enrollment of 48 is below the median of 72 across 712 interventional studies indexed under Gastroesophageal Reflux.
Browse Gastroesophageal Reflux studies →Takeda is the lead sponsor of 1,002 studies on the registry; 92 are open to participants now.
Of its 173 completed or terminated interventional studies of FDA-regulated products, 149 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
TAK-438 10 mg tablets, orally, once, daily, for 7 days.
Drug: TAK-438
TAK-438 20 mg tablets, orally, once, daily, for 7 days.
Drug: TAK-438
TAK-438 40 mg tablets, orally, once, daily, for 7 days.
Drug: TAK-438
TAK-438 30 mg tablets, orally, once, daily, for 7 days.
Drug: TAK-438
TAK-438 placebo-matching tablets, orally, once, daily, for 7 days.
Drug: TAK-438 Placebo
TAK-438 tablets
TAK-438 placebo-matching tablets
AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).
Time frame: Days 1 and 7
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.
Time frame: Days 1 and 7
AUC(0-tau): Area Under the Plasma Concentration-time Curve from Time 0 to Time tau Over the Dosing Interval for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
AUC(0-tau) is a measure of the area under the plasma concentration-time curve from time 0 to time tau over a dosing interval, where tau is the length of the dosing interval.
Time frame: Days 1 and 7
Cmax: Maximum Observed Plasma Concentration for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Days 1 and 7
Cmin,ss: Minimum Observed Plasma Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
Time frame: Day 7
Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
Time frame: Day 7
(Cmax-Cmin)/Cavg: Fluctuation of Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
(Cmax-Cmin)/Cavg, where Cmin is the minimum observed plasma concentration and Cavg is the average plasma concentration at steady state.
Time frame: Day 7
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.
Time frame: Days 1 and 7
Terminal Elimination Rate Constant (λz) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
Terminal elimination rate constant (λz) is the rate at which drugs are eliminated from the body.
Time frame: Days 1 and 7
Terminal Elimination Half-life (T1/2) Pharmacokinetic Parameter for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
Time frame: Days 1 and 7
Apparent Clearance (CL/F) Pharmacokinetic Parameter for TAK-438
CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-24), expressed in L/hr.
Time frame: Days 1 and 7
Apparent Volume of Distribution (Vz/F) for TAK-438
Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz.
Time frame: Days 1 and 7
Ae(0-t): Total Amount of Drug Excreted in Urine from Time 0 to Time T for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
Ae(0-t) is the total amount of drug excreted in urine from time 0 to t, where t is 24 hours on Day 1 and 48 hours on Day 7.
Time frame: Day 1 and Day 7
Ae(0-tau): Total Amount of Drug Excreted in Urine from Time 0 to Time tau for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
Ae(0-tau) is the total amount of drug excreted in urine from time 0 to tau, where tau equals 24 hours.
Time frame: Day 1 and Day 7
Renal Clearance (CLr) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul
CLr is a measure of apparent clearance of the drug from the urine calculated as total amount excreted in the urine from time 0 to 24 hours postdose / plasma area under the curve from time 0 to 24 hours post-dose.
Time frame: Day 1 and Day 7
Fraction of TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Excreted in Urine (Fe)
Fe is a measure of the fraction of drug excreted in urine and is calculated as Fe = (total amount excreted in the urine from time 0 to 24 hours post-dose / dose)×100.
Time frame: Day 1 and Day 7
Physical Examination Findings
A baseline physical examination (defined as the pretreatment assessment immediately prior to the start of study drug) will consist of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; (11) genitourinary system; and (12) other. All subsequent physical examinations should assess clinically significant changes from the baseline examination.
Time frame: Baseline up to Day 9
Number of Participants With Potentially Clinically Significant Vital Sign Findings
Participants with at least one potentially clinically significant post-baseline vital sign finding. Vital signs will include body temperature (oral temperature), sitting blood pressure (after sitting for 5 minutes), and pulse (bpm).
Time frame: Baseline up to Day 9
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings
Full 12-lead ECGs will be recorded using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (using Bazett correction; QTcB) intervals. The investigator or other qualified physician will interpret each ECG using one of the following categories: within normal limits, abnormal but not clinically significant, or abnormal and clinically significant.
Time frame: Baseline to Day 9
Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings
Laboratory tests for hematology, serum chemistries, coagulation tests, and urinalysis will be performed.
Time frame: Baseline up to Day 9
Number of Participants With Treatment-Emergent Adverse Events (AEs)
Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 7 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.
Time frame: Baseline up to Day 9
Safety of TAK-438
Assessed by physical examination, ECG, and safety tests of blood/urine
Time frame: 3 months
Tolerability of TAK-438
Assessed by adverse events
Time frame: 3 months
Pharmacokinetic analysis of plasma TAK-438 concentrations
Primary pharmacokinetic parameters (AUC (0-tlqc), AUC (0-inf), Cmax) for TAK-438 and its metabolites M-I, M-II, M-III and M-IV-Sul will be subject to statistical analysis
Time frame: 3 months
Pharmacodynamic measurement for assay of gastric pH, measurement of gastrin, pepsinogen I, pepsinogen II and the pepsinogen I/II ratio in plasma samples
Time frame: 3 months
Percentage of Time the pH is Greater than pH 4 and pH 5 over a 24 Hour Period
Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 24-hour period at Baseline and over a 24-hour period following the administration of study on Days 1, 4 and 7.
Time frame: Over a 24-hour period at Baseline and over a 24-hour period following the administration of study on Days 1, 4 and 7
Percentage of Time the pH is Greater than pH 4 and pH 5 over a 48 Hour Period
Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 48-hour period following the administration of study drug on Day 7.
Time frame: Over a 48-hour period following the administration of study on Day 7
Percentage of Time the PH is Greater than pH 4 and pH 5 from 8 PM to 8 AM
Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 12-hour period from 8 PM to 8 AM to assess nocturnal pH.
Time frame: Over a 12-hour period from 8 PM to 8 AM on Days 1, 4 and 7
Total Amount of Gastrin in Plasma
Time frame: Predose Days 1 through 7 and Days 8 and 9
Total Amount of Pepsinogen I in Plasma
Time frame: Predose Days 1 through 7 and Days 8 and 9
Total Amount of Pepsinogen II in Plasma
Time frame: Predose Days 1 through 7 and Days 8 and 9
Pepsinogen I/II Ratio in Plasma
Time frame: Predose Days 1 through 7 and Days 8 and 9
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Takeda